Xeris sees FY23 revenue at top end of forecast range; shares rise

Xeris Biopharma Holdings

04/01/2024 15:20

** Shares of therapy developer Xeris Biopharma  XERS.O  rise
~8% to $2.42, set to snap a three-day losing streak
    ** Co says it expects to report FY 2023 revenue at the high
end of its forecast range of $160 mln to $165 mln
    ** Expects to record more than $72 mln in cash, cash
equivalents, and short-term investments
    ** XERS scheduled to report its Q4 and FY 2023 results on or
about March 6, 2024
    ** Stock was up 76.7% in 2023

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))